Kendall Capital Partners
Venture capitalBoston · Seed–Growth · 6 people tracked
Investment thesis
Kendall Capital Partners invests in transformative life sciences and healthcare innovations addressing urgent global medical needs. The firm focuses on breakthrough science in gene and cell therapies, precision immunotherapies, advanced drug delivery systems, and AI-powered diagnostic and manufacturing platforms. Investment decisions are informed by a world-class scientific advisory board and partnerships with elite research institutions including MIT, Harvard, and Columbia. The firm seeks to de-risk innovations through rigorous scientific and operational diligence, build enduring companies, and deliver measurable health impact alongside financial returns for institutional investors, family offices, and high-net-worth individuals.
Source: firm website, verified Aug 6, 2026.
Team · 6 people
from the firm's website & public directories
What they invest in
from 10 of 13 portfolio companiesBiotech ×8Healthtech ×4Medical Devices ×2AI & Machine Learning ×1Digital Health ×1Longevity ×1
HQs:United States×11
Investments · 13 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12023 · 22019 · 12017 · 12016 · 32015 · 110 dated
BiotechCambridge, US
Thomas A. Collet(Executive Officer, Director)Carlo Traverso Giovanni(Director)
BoardJoshua Korzenik(Director)
Board seatRobert Langer· per SEC Form D · $1M raise · filed Aug 2023
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
Board seatGeorge M. Church· per SEC Form D · $3M raise · filed Aug 2016
Co-investorsAlta PartnersARCH Venture PartnersCatalio Capital Management, LPKhosla VenturesOUP (Osage University Partners)b2venture
EpiBone engineers bone tissue from stem cells for regenerative medicine and clinical reconstruction, serving patients requiring bone grafts or craniofacial repair.
BiotechHealthtechMedical DevicesNew York, US
Nina Tandon(Co-Founder, CEO)Sarindr Bhumiratana(Co-Founder)Gordana Vunjak-Novakovic(Director)Elma Hawkins(Director)
BoardDavid Zhu(Director)
Board seatRobert Langer· per SEC Form D
Co-investorsBeresford VenturesEMV CapitalHackensack Meridian Health Bear's DenPlum Alley InvestmentsTachyon VenturesTech Council Ventures
BiotechWoburn, US
David Lucchino(Executive Officer, Director)Christopher R. Loose(Executive Officer)
BoardMarc Kozin(Director)Marc Cohen(Director)Timothy Barberich(Director)
Board seatRobert Langer· per SEC Form D · $62M raise · filed Jul 2019
Co-investorsvenBio PartnersAlexandria
BiotechWatertown, US
Carlo Giovanni Traverso(Director)Amy W. Schulman(Executive Officer, Director)inRobert S. Langer(Director)
BoardZafi Avnur(Director)Edmund Harrigan(Director)Catherine Reynolds(Director)
Board seatRobert Langer· per SEC Form D · $23.1M raise · filed Apr 2017
Co-investorsBill & Melinda Gates FoundationPolaris Partners
HealthtechLexington, US
Robert S. Langer(Director)Michael J. Cima(Director)David Neafus(Executive Officer)Cheryl R. Blanchard(Executive Officer, Director)Robert Farra(Executive Officer)
BoardTerrance G. McGuire(Director)
Board seatRobert Langer· per SEC Form D · $18.6M raise · filed Jun 2015
Co-investorsPolaris Partners
A biotech company developing a multi-layered polymer delivery system for sustained-release vaccine and medication administration via single injection.
Cambridge, US
Board seatRobert Langer· per SEC Form D
BiotechCambridge, US
Torben Straight Nissen(Executive Officer, Director)Joanne Protano(Executive Officer)David Epstein(Director)Harvey F. Lodish(Director)Michael Rosenblatt(Director)Roger Pomerantz(Director)
Board seatRobert Langer· per SEC Form D · $120M raise · filed Jun 2017
Co-investorsFlagship Pioneering
BiotechWatertown, US
Omid Farokhzad(Director)Robert S. Langer, Jr.(Director)Andrew J. Fromkin(Executive Officer, Director)Leila Alland(Executive Officer)Richard Wooster(Executive Officer)Omid C. Farokhzad(Director)
Board seatRobert Langer· per SEC Form D · $38M raise · filed Feb 2017
Co-investors+ND Capital
Eyenuk provides autonomous AI-based eye exams performed at the point of care to detect eye conditions including diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucomatous signs.
AI & Machine LearningDigital HealthHealthtechMedical DevicesWoodland Hills, US
Kaushal Solanki(Director)Gaurav Agarwal(Executive Officer, Director)
BoardMads Dall(Director)Zina Affas Besse(Director)Marie-Louise Little(Director)
Rejuvenate Bio is a biotechnology company developing gene therapies aimed at treating age-related diseases, with a pipeline that includes a canine mitral valve disease (MVD) program.
BiotechHealthtechLongevitySan Diego, US
Noah Davidsohn(CSO, Co-Founder)Daniel Oliver(CEO, Co-Founder)George Church(Co-Founder and SAB)Deborah Ascheim(Chief Medical Officer)
BoardDavid Zhu(Director)
Co-investorsCompanion FundConnecticut InnovationsKdT Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companies
Rejuvenate Bio · intelligence360.news · Jul 30, 2026
Eyenuk · intelligence360.news · Jul 20, 2026
eGenesis · salestools.io · Aug 23, 2025
Frequently asked questions
- How many investments has Kendall Capital Partners made?
- Kendall Capital Partners has 6 tracked investments, including 2 dated in the last 24 months.
- What stage does Kendall Capital Partners invest at?
- Kendall Capital Partners invests at the Seed, Series A, Series B, Growth stages.
- What sectors does Kendall Capital Partners focus on?
- Kendall Capital Partners focuses on AI & Machine Learning, Biotech, Digital Health, Medical Devices.
- Where is Kendall Capital Partners located?
- Kendall Capital Partners is headquartered in Boston, US.
- Who does Kendall Capital Partners co-invest with?
- Kendall Capital Partners most often shares deals with Companion Fund, Connecticut Innovations, EMV Capital, among 8 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.